Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo

Urology

Volumn 48, Issue 1, 1996, Pages 164-170

  Pienta, Kenneth J ^a,b   Naik, Harmesh ^a   Lehr, Jeffrey E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRAMUSTINE; ETOPOSIDE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT;

EID: 0030197637     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00109-4     Document Type: Article

References (40)

1. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol. 3:1985;827-841.
2. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone resistant prostate cancer. Cancer. 71:1993;1098-1109. (suppl).
3. Pienta KJ, Partin AW, Coffey DS. Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res. 49:1989;2525-2532.
4. Pienta KJ, Getzenberg RH, Coffey DS. Cell structure and DNA organization. Crit Rev Eukaryot Gene Exp. 1:1991;355-385.
5. Isaacs JT, Barrack ER, Isaacs WB, Coffey DS. The relationship of cellular structure and function: the matrix system. Prog Clin Biol Res. 75A:1981;1-24.
6. Pienta KJ, Coffey DS. Nuclear-cytoskeletal interactions: evidence for physical connections between the nucleus and cell periphery and their alteration by transformation. J Cell Biochem. 49:1992;357-365.
7. Ben-Ze'ev A. The cytoskeleton in cancer cells. Biochim Biophys Acta. 780:1980;197-212.
8. Bissell MJ, Matie C, Lazlo A, Parry G. The influence of the extracellular matrix on normal and transformed phenotypes in culture. J Cell Biol. 91:1981;163A.
9. Pienta KJ, Coffey DS. Cell motility as a chemotherapeutic target. Cancer Study. 11:1991;255-263.
10. Speicher LA, Barone L, Tew KD. Combined antimicrotubule activity of estramustine and Taxol in human prostatic carcinoma cell lines. Cancer Res. 52:1992;4433-4440.
11. Fernandes DJ, Catapano CV. Nuclear matrix targets for anticancer agents. Cancer Cells. 3:1991;134-140.
12. Pienta KJ, Lehr JE. Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J Urol. 149:1993;1622-1625.
13. Pienta KJ, Redman BG, Hussain M, Cummings G, Esper PS, Appel C, Flaherty LE. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol. 12:1994;2005-2012.
14. Pienta KJ, Redman BG, Hussain M, Esper PS, Flaherty LE. Preclinical and clinical inhibition of prostate cancer growth by estamustine and etoposide. Cancer. 75:1995;1920-1926.
15. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA. 77:1980;1561-1565.
16. Fuchs DA, Johnson RK. Cytological evidence that Taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep. 62:1978;1219-1222.
17. Manfredi JJ, Horwitz SB. Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther. 25:1984;83-125.
18. Crossin KL, Carney DH. Microtubule stabilization by Taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factor. Cell. 27:1981;341-350.
19. Stearns ME, Wang M. Taxol blocks processes essential for prostate tumor cell (PC3-ML) invasion and metastasis. Cancer Res. 52:1992;3776-3781.
20. Roth BJ, Yeap BY, Wilding G, Kasimis B, Mcleod D, Loehrer PJ. Taxol in advanced, hormone-refractory carcinoma of the prostate: a phase II trial of the Eastern Cooperative Oncology Group. Cancer. 72:1993;2457-2460.
21. Stearns ME, Tew KD. Antimicrotubule effects of estramustine, an antiprostatic tumor drug. Cancer Res. 45:1985;3891-3897.
22. Dahllof B, Billstrom A, Cabral F, Hartley-Asp B. Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res. 53:1993;4573-4581.
23. Roth BJ. Combination chemotherapy in advanced prostate cancer: a silk purse? J Clin Oncol. 12:1994;2001-2002.
24. Hudes G, Nathan F, Chapman A, Greenberg R, McAleer C. Combined antimicrotubule therapy of metastatic prostate cancer with 96-hr paclitaxel and estramustine: activity in hormone-refractory disease. Proc Annu Meet Am Soc Clin Oncol. 14:1995;A622.
25. Moraga D, Rivas-Berrios A, Farias G, Wallin M, Maccioni RB. Estramustine-phosphate binds to a tubulin binding domain on microtubule-associated proteins MAP-2 and tau. Biochim Biophys Acta. 1121:1992;97-103.
26. De Kernion JN, Murphy GP, Priore R. Comparison of flutamide and Emcyt in hormone-refractory metastatic prostate cancer. Urology. 31:1988;312-317.
27. Elomaa I, Kellokumpu-Lehtinen P, Rannikko S, Alfthan O. Hormone-resistant metastatic prostate cancer: comparisons between estramustine phosphate and low-dose epirubicin treatments. Eur Urology. 19:1991;12-15.
28. Murphy GP, Slack NH, Mittelman A. Use of estramustine phosphate in prostate cancer by the National Prostatic Cancer Project and by Roswell Park Memorial Institute. Urology. 23:1984;54-61. (suppl).
29. Murphy GP, Slack NH, Mittelman A. Experiences with estramustine phosphate in prostate cancer. Semin Oncol. 10:1983;34-45. (suppl).
30. Johansson LE, Anderson SO, Beckman KW, Zador G. Clinical evaluation with long term follow up of flutamide and estramustine as initial treatment of metastatic carcinoma of the prostate. Am J Clin Oncol. 11:1988;183-186. (suppl).
31. Newling DWW, Fossa S, Tunn U, Kurth KH, DePauw M, Sylvester R. Comparison of the effects of high dose estramustine phosphate and mitomycin C on the time to progression and length of survival of patients with progressive, advanced endocrine-independent prostatic cancer: an interim analysis of EORTC-GU group study no. 30865. J Steroid Biochem Molec Biol. 37:1988;971-975.
32. Akaza H, Isurugi K, Oishi Y, Kitajima K, Sawamura Y, Baba S, Yoshida K, Otani M, Harada M, Gunji A, et al. The Tokyo Estracyt Study Group: a prospective, randomized controlled study on the treatment of stage C and stage D prostatic cancer with estracyt in combination with other chemotherapeutic agents. Jpn J Clin Oncol. 18:1988;343-355.
33. Chatelut E, Chevreau C, Blancy E, Lequellec A, Canal P, Roche H, Houin G, Bugat R. Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small cell lung carcinoma. Cancer Chemother Pharmacol. 26:1989;365-368.
34. Miller AA, Stewart CF, Tolley EA. Clinical pharmacokinetics on continuous-infusion etoposide. Cancer Chemother Pharmacol. 25:1990;361-366.
35. Greco FA, Johnson DH, Hainsworth JD. Chronic oral etoposide. Cancer. 67:1991;303-309. (suppl).
36. Walther PJ, Williams SD, Troner M, Greco FA, Birch R, Einhorn LH. Phase II study of etoposide for carcinoma of the prostate. Cancer Treat Rep. 70:1986;771-772.
37. Scher HI, Sternberg, Heston WD, Watson RC, Niedzwiecki D, Smart T, Hollander P, Yagoda A. Etoposide in prostatic cancer: experimental studies and phase II trials in patients with bidimensionally measurable disease. Cancer Chemother Pharmacol. 18:1986;24-26.
38. Hussain MH, Pienta KJ, Redman BG, Cummings GD, Flaherty LE. Oral etoposide in the treatment of hormone-refractory prostate cancer. Cancer. 74:1994;100-103.
39. Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol. 91:1981;479-487.
40. Hamel E, del Campo AA, Lowe MC, Lin CM. Interactions of Taxol, microtubule-associated proteins, and guanine nucleotides in tubulin polymerization. J Biol Chem. 256:1981;11887-11894.